PE20190381A1 - Oligonucleotidos antisentido para modular la expresion de htra1 - Google Patents

Oligonucleotidos antisentido para modular la expresion de htra1

Info

Publication number
PE20190381A1
PE20190381A1 PE2018003308A PE2018003308A PE20190381A1 PE 20190381 A1 PE20190381 A1 PE 20190381A1 PE 2018003308 A PE2018003308 A PE 2018003308A PE 2018003308 A PE2018003308 A PE 2018003308A PE 20190381 A1 PE20190381 A1 PE 20190381A1
Authority
PE
Peru
Prior art keywords
htra1
expression
modulate
sense oligonucleotides
refers
Prior art date
Application number
PE2018003308A
Other languages
English (en)
Inventor
Peter Hagedorn
Susanne Kammler
Søren Ottosen
Sindri Traustason
Heidi Rye Hudlebusch
Lykke Pedersen
Roberto Iacone
Original Assignee
Hoffmann La Roche
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hoffmann La Roche filed Critical Hoffmann La Roche
Publication of PE20190381A1 publication Critical patent/PE20190381A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/323—Chemical structure of the sugar modified ring structure
    • C12N2310/3231—Chemical structure of the sugar modified ring structure having an additional ring, e.g. LNA, ENA
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/33—Chemical structure of the base
    • C12N2310/334—Modified C
    • C12N2310/3341—5-Methylcytosine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/341—Gapmers, i.e. of the type ===---===
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/344—Position-specific modifications, e.g. on every purine, at the 3'-end
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/34—Spatial arrangement of the modifications
    • C12N2310/346—Spatial arrangement of the modifications having a combination of backbone and sugar modifications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate

Abstract

SE REFIERE A UN OLIGONUCLEOTIDO ANTISENTIDO DE FORMULA (I) DE SEQ ID NO: 143 Y A UNA SAL FARMACEUTICAMENTE ACEPTABLE DEL MISMO TAL COMO LA SAL SODICA O LA SAL POTASICA. TAMBIEN SE REFIERE A UNA COMPOSICION FARMACEUTICA QUE COMPRENDE DICHO OLIGONUCLEOTIDO ANTISENTIDO, EL CUAL MODULA LA EXPRESION DE HTRA1 SIENDO UTIL PARA TRATAR O PREVENIR LA DEGENERACION MACULAR ASOCIADA A LA EDAD
PE2018003308A 2016-07-01 2017-06-28 Oligonucleotidos antisentido para modular la expresion de htra1 PE20190381A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP16177508 2016-07-01
EP17170129 2017-05-09

Publications (1)

Publication Number Publication Date
PE20190381A1 true PE20190381A1 (es) 2019-03-08

Family

ID=59295175

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2018003308A PE20190381A1 (es) 2016-07-01 2017-06-28 Oligonucleotidos antisentido para modular la expresion de htra1

Country Status (21)

Country Link
US (2) US10519450B2 (es)
EP (1) EP3478839A1 (es)
JP (3) JP7060525B2 (es)
KR (1) KR20190025970A (es)
CN (1) CN109415732B (es)
AU (1) AU2017289204A1 (es)
BR (1) BR112018077321A2 (es)
CA (1) CA3026855A1 (es)
CL (1) CL2018003698A1 (es)
CO (1) CO2018013240A2 (es)
CR (1) CR20180606A (es)
IL (1) IL263489A (es)
MA (1) MA45620A (es)
MX (1) MX2018015722A (es)
PE (1) PE20190381A1 (es)
PH (1) PH12018502707A1 (es)
RU (1) RU2019101298A (es)
SG (2) SG11201811554SA (es)
TW (1) TW201803990A (es)
WO (1) WO2018002105A1 (es)
ZA (1) ZA201808291B (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7164521B2 (ja) 2016-06-21 2022-11-01 オリオン・オフサルモロジー・エルエルシー 炭素環式プロリンアミド誘導体
HUE064412T2 (hu) 2016-06-21 2024-03-28 Orion Ophthalmology LLC Heterociklusos prolinamid-származékok
BR112018077321A2 (pt) 2016-07-01 2019-04-24 F. Hoffmann-La Roche Ag oligonucleotídeos anti-sentido para modular a expressão de htra1
EP3728590A1 (en) 2017-12-22 2020-10-28 Roche Innovation Center Copenhagen A/S Novel thiophosphoramidites
BR112020010090A2 (pt) 2017-12-22 2020-11-03 Roche Innovation Center Copenhagen A/S oligonucleotídeo gapmer, sal farmaceuticamente aceitável do mesmo, conjugado, composição farmacêutica e uso dos mesmos
AU2018386524A1 (en) 2017-12-22 2020-07-02 Roche Innovation Center Copenhagen A/S Oligonucleotides comprising a phosphorodithioate internucleoside linkage
EP3752612A4 (en) 2018-02-12 2021-11-10 Ionis Pharmaceuticals, Inc. MODIFIED COMPOUNDS AND USES THEREOF
WO2020007772A1 (en) * 2018-07-02 2020-01-09 Roche Innovation Center Copenhagen A/S Antisense oligonucleotides targeting gbp-1
WO2020109343A1 (en) * 2018-11-29 2020-06-04 F. Hoffmann-La Roche Ag Combination therapy for treatment of macular degeneration
WO2020109344A1 (en) * 2018-11-29 2020-06-04 F. Hoffmann-La Roche Ag Occular administration device for antisense oligonucleotides

Family Cites Families (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3756313B2 (ja) 1997-03-07 2006-03-15 武 今西 新規ビシクロヌクレオシド及びオリゴヌクレオチド類縁体
EP2341057A3 (en) 1997-09-12 2011-11-23 Exiqon A/S Oligonucleotide Analogues
WO2000008134A2 (en) 1998-08-03 2000-02-17 Novartis Ag HUMAN HtrA SERINE PROTEASE
AU758956B2 (en) 1999-02-12 2003-04-03 Daiichi Sankyo Company, Limited Novel nucleosides and oligonucleotide analogues
EP1178999B1 (en) 1999-05-04 2007-03-14 Santaris Pharma A/S L-ribo-lna analogues
US6617442B1 (en) 1999-09-30 2003-09-09 Isis Pharmaceuticals, Inc. Human Rnase H1 and oligonucleotide compositions thereof
AU2003281969B2 (en) 2002-11-18 2011-01-27 Roche Innovation Center Copenhagen A/S Amino-LNA, thio-LNA and alpha-L-oxy-LN
EP1888083B1 (en) 2005-05-24 2011-12-28 Isis Pharmaceuticals, Inc. Compositions and their uses directed to lmw-ptpase
WO2007031091A2 (en) 2005-09-15 2007-03-22 Santaris Pharma A/S Rna antagonist compounds for the modulation of p21 ras expression
CA2640171C (en) 2006-01-27 2014-10-28 Isis Pharmaceuticals, Inc. 6-modified bicyclic nucleic acid analogs
US7666854B2 (en) 2006-05-11 2010-02-23 Isis Pharmaceuticals, Inc. Bis-modified bicyclic nucleic acid analogs
ES2389737T3 (es) 2006-05-11 2012-10-31 Isis Pharmaceuticals, Inc. Análogos de ácidos nucleicos bicíclicos modificados en 5'
DK2044223T3 (da) * 2006-07-26 2012-10-08 Univ Yale Inc Diagnosticering og behandling af aldersrelateret makuladegeneration
WO2008067040A2 (en) * 2006-10-06 2008-06-05 University Of Utah Research Foundation Method of detecting ocular diseases and pathologic conditions and treatment of same
EP2097448A4 (en) 2006-12-22 2010-07-21 Univ Utah Res Found METHOD FOR DETECTING DISEASES AND OCULAR DISEASE CONDITIONS AND TREATMENT THEREOF
WO2008150729A2 (en) 2007-05-30 2008-12-11 Isis Pharmaceuticals, Inc. N-substituted-aminomethylene bridged bicyclic nucleic acid analogs
EP2173760B2 (en) 2007-06-08 2015-11-04 Isis Pharmaceuticals, Inc. Carbocyclic bicyclic nucleic acid analogs
TW200911290A (en) * 2007-07-02 2009-03-16 Alcon Res Ltd RNAI-mediated inhibition of HTRA1 for treatment of macular degeneration
US8278283B2 (en) 2007-07-05 2012-10-02 Isis Pharmaceuticals, Inc. 6-disubstituted or unsaturated bicyclic nucleic acid analogs
CA2704809A1 (en) 2007-11-01 2009-05-07 University Of Iowa Research Foundation Rca locus analysis to assess susceptibility to amd and mpgnii
WO2009067647A1 (en) 2007-11-21 2009-05-28 Isis Pharmaceuticals, Inc. Carbocyclic alpha-l-bicyclic nucleic acid analogs
EP2356129B1 (en) 2008-09-24 2013-04-03 Isis Pharmaceuticals, Inc. Substituted alpha-l-bicyclic nucleosides
EP2462153B1 (en) 2009-08-06 2015-07-29 Isis Pharmaceuticals, Inc. Bicyclic cyclohexose nucleic acid analogs
WO2011156202A1 (en) 2010-06-08 2011-12-15 Isis Pharmaceuticals, Inc. Substituted 2 '-amino and 2 '-thio-bicyclic nucleosides and oligomeric compounds prepared therefrom
FR2965278B1 (fr) 2010-09-23 2014-10-10 Univ Caen Basse Normandie Procede d'obtention in vitro ou ex vivo de chondrocytes et leurs utilisations
CN104136451A (zh) 2011-09-07 2014-11-05 玛瑞纳生物技术有限公司 具有构象限制的单体的核酸化合物的合成和用途
US9221864B2 (en) 2012-04-09 2015-12-29 Isis Pharmaceuticals, Inc. Tricyclic nucleic acid analogs
EP2850184A4 (en) 2012-05-16 2016-01-27 Rana Therapeutics Inc COMPOSITIONS AND METHOD FOR MODULATING GENE EXPRESSION
EP2920304B1 (en) 2012-11-15 2019-03-06 Roche Innovation Center Copenhagen A/S Oligonucleotide conjugates
KR102162324B1 (ko) 2015-10-30 2020-10-07 제넨테크, 인크. 항-HtrA1 항체 및 이의 사용 방법
BR112018077321A2 (pt) 2016-07-01 2019-04-24 F. Hoffmann-La Roche Ag oligonucleotídeos anti-sentido para modular a expressão de htra1
JP7033591B2 (ja) 2016-11-11 2022-03-10 ロシュ イノベーション センター コペンハーゲン エーエス 治療用オリゴヌクレオチドの捕捉および検出
US20190055564A1 (en) 2017-06-01 2019-02-21 F. Hoffmann-La Roche Ag Antisense oligonucleotides for modulating htra1 expression

Also Published As

Publication number Publication date
BR112018077321A2 (pt) 2019-04-24
JP7060525B2 (ja) 2022-04-26
RU2019101298A (ru) 2020-08-03
MX2018015722A (es) 2019-05-27
US10519450B2 (en) 2019-12-31
TW201803990A (zh) 2018-02-01
CO2018013240A2 (es) 2018-12-14
PH12018502707A1 (en) 2019-11-11
US20180002701A1 (en) 2018-01-04
JP7416852B2 (ja) 2024-01-17
CA3026855A1 (en) 2018-01-04
JP2019522987A (ja) 2019-08-22
CN109415732B (zh) 2024-01-02
CR20180606A (es) 2019-02-14
ZA201808291B (en) 2019-10-30
JP2022106785A (ja) 2022-07-20
US20200399641A1 (en) 2020-12-24
WO2018002105A1 (en) 2018-01-04
MA45620A (fr) 2019-05-08
SG10202005885VA (en) 2020-07-29
AU2017289204A1 (en) 2019-01-17
RU2019101298A3 (es) 2021-01-26
CL2018003698A1 (es) 2019-04-05
IL263489A (en) 2019-01-31
KR20190025970A (ko) 2019-03-12
SG11201811554SA (en) 2019-01-30
JP2024029178A (ja) 2024-03-05
CN109415732A (zh) 2019-03-01
EP3478839A1 (en) 2019-05-08

Similar Documents

Publication Publication Date Title
PE20190381A1 (es) Oligonucleotidos antisentido para modular la expresion de htra1
CL2021001292A1 (es) Terapia de combinación que incluye un inhibidor de krasg12c y uno o más agentes farmacéuticamente activos adicionales para el tratamiento de cánceres
PE20181330A1 (es) Dinucleotidos ciclicos para tratar condiciones asociadas con actividad del estimulador de genes del interferon (sting) tales como cancer
PE20190626A1 (es) Composiciones y metodos para modular la expresion del factor b del complemento
CL2019002204A1 (es) Compuestos inhibidores del vih.
CO2019015090A2 (es) Métodos de tratamiento para la fibrosis cística
CL2019001565A1 (es) Composición farmacéutica para prevenir o tratar el cáncer, comprendiendo el polímorfo cristalino del hexoxido tetraarsénico.
CO2019004034A2 (es) Compuesto de piridina
CL2020000886A1 (es) Derivados de 1-benzil-2-imino-4-fenil-5-oxoimidazolidina como inhibidores de la proteasa del vih.
BR112017011923A2 (pt) bactéria modificada para tratar doenças associadas com hiperamonemia
DOP2016000194A (es) 2-amino-3,5,5-trifluoro-3,4,5,6-tetrahidropiridinas como inhibidores de bace1 para el tratamiento de la enfermedad de alzheimer
PE20191047A1 (es) Compuestos y metodos para reducir de la expresion de atxn3
CR20160564A (es) Dinucleótidos cíclicos como moduladores de sting
UY36075A (es) Derivados de tubulisina
PE20142404A1 (es) Compuestos de microarn y metodos de modulacion de la actividad de mir-21
UY37182A (es) Derivados de indolina sustituidos como inhibidores de la replicación viral del dengue
PE20181085A1 (es) Composiciones y metodos para modular la expresion de angiotensinogeno
BR112016022742A2 (pt) composições e métodos para modular a expressão de receptor de hormônio do crescimento
BR112019000693A2 (pt) composições de muc1- car e métodos para uso
TR201818825T4 (tr) Kardi̇yak hi̇pertrofi̇ni̇n tedavi̇si̇ne ve tanisina yöneli̇k lncrnalar
CL2018003044A1 (es) 6-aminopiridina-3-yl tiazoles como moduladores de ror.
CL2017000382A1 (es) Compuestos bicíclicos sustituidos
CL2021001388A1 (es) Compuestos útiles en la terapia para el vih
MX2020003732A (es) Derivado de anillo fusionado como inhibidor del receptor a2a.
CL2021000030A1 (es) Uso de estimuladores de la sgc para el tratamiento de trastornos mitocondriales